Mr Thomas Gerald Morgan, MD | |
3410 Futures Dr, South Sioux City, NE 68776-3917 | |
(712) 252-2477 | |
(712) 252-5920 |
Full Name | Mr Thomas Gerald Morgan |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 17 Years |
Location | 3410 Futures Dr, South Sioux City, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073600755 | NPI | - | NPPES |
1244374 | Other | CSA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 40914 (Iowa) | Secondary |
207Q00000X | Family Medicine | 27764 (Nebraska) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Siouxland Community Health Center | 9931099546 | 39 |
Siouxland Community Health Center | 9931099546 | 39 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Entity Name | Pocahontas Community Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1609989581 PECOS PAC ID: 7012820012 Enrollment ID: O20031106000417 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Entity Name | Siouxland Medical Education Foundation, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1336127828 PECOS PAC ID: 6608761101 Enrollment ID: O20040216000191 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Entity Name | Northwest Iowa Hospital Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215962550 PECOS PAC ID: 0749198026 Enrollment ID: O20040217000619 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Entity Name | Siouxland Community Health Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1558355305 PECOS PAC ID: 9931099546 Enrollment ID: O20040317001270 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Entity Name | Northwest Iowa Emergency Physicians, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1871519207 PECOS PAC ID: 3971495797 Enrollment ID: O20040326000817 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Entity Name | Van Buren County Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1316063076 PECOS PAC ID: 7214829530 Enrollment ID: O20040329001814 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Entity Name | Ida County Iowa Community Hospital |
---|---|
Entity Type | Part A Provider - Critical Access Hospital |
Entity Identifiers | NPI Number: 1265461180 PECOS PAC ID: 9537070826 Enrollment ID: O20061104000191 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Mr Thomas Gerald Morgan, MD 3410 Futures Dr, South Sioux City, NE 68776-3917 Ph: (712) 252-2477 | Mr Thomas Gerald Morgan, MD 3410 Futures Dr, South Sioux City, NE 68776-3917 Ph: (712) 252-2477 |
News Archive
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients.
› Verified 3 days ago
Dr. Michael Brenner, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3250 Plaza Dr, South Sioux City, NE 68776 Phone: 402-412-4220 Fax: 402-412-4222 | |
Michael L Hattan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3250 Plaza Dr, South Sioux City, NE 68776 Phone: 402-412-4220 Fax: 712-494-1365 | |
Kevin J Folchert, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3250 Plaza Dr, South Sioux City, NE 68776 Phone: 402-412-4220 Fax: 402-494-1365 | |
Suhair Afana Najdawi, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 501 1st Ave, South Sioux City, NE 68776 Phone: 402-494-3064 Fax: 712-294-7299 | |
Marissa Kay Jewel Lundeen, APRN Family Medicine Medicare: Medicare Enrolled Practice Location: 550 Kemon Dr, South Sioux City, NE 68776 Phone: 712-560-2755 | |
Thomas J Wente, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3250 Plaza Dr, South Sioux City, NE 68776 Phone: 402-412-4220 Fax: 402-494-1365 |